<DOC>
	<DOCNO>NCT01652482</DOCNO>
	<brief_summary>This open-label , randomize , multicenter , Phase 2 study evaluate safety efficacy MEHD7945A combine FOLFIRI ( folinic acid [ leucovorin ] , 5-fluorouracil [ 5-FU ] , irinotecan ) chemotherapy compare cetuximab plus FOLFIRI participant Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) wild-type mCRC progress first-line oxaliplatin-containing chemotherapy metastatic disease . Participants randomize receive FOLFIRI chemotherapy plus either MEHD7945A cetuximab . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>Safety Efficacy Study MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI Second Line Therapy Participants With KRAS Wild-Type Metastatic Colorectal Cancer ( mCRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma colon and/or rectum , KRAS wildtype status Progressive disease firstline oxaliplatincontaining regimen mCRC ; participant must receive oxaliplatincontaining chemotherapy great equal ( &gt; /= ) 3 month ; one prior chemotherapy regimen metastatic disease allow Measurable disease per modify Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST v1.1 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic endorgan function Prior treatment irinotecan Prior treatment investigational approve human epidermal growth factor receptor ( HER ) target agent Last antitumor therapy within 4 week prior Cycle 1 , Day 1 Leptomeningeal disease manifestation current malignancy Active infection require intravenous antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug Current severe , uncontrolled systemic disease Known human immunodeficiency virus ( HIV ) infection Untreated/active central nervous system metastasis ( progress require anticonvulsant corticosteroid symptomatic control ) Pregnant lactate woman Malignancies colorectal cancer within 5 year prior randomization , except adequately treat basal squamous cell skin cancer carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>